AmideBio
Boulder, US · Founded 2009 · Colorado LLC
Find your way into AmideBio
AmideBio discovers and designs peptide therapeutics for metabolic diseases, using in-silico design and its BioPure process to produce ultrapure peptides. It also sells manufactured peptides and offers custom synthesis services to the biopharmaceutical industry and research community, aiming to license drug candidates at or before the IND stage.
Founders & leadership
AmideBio was founded in 2009 by Michael H. B. Stowell.
MH
Michael H. B. StowellCSO, Founder and Board Member
MP
Mikhail PlamExecutive
PF
Pawel Fludzinski, PhDCEO, President and Board Member
PF
Pawel FludzinskiinCEO, President and Board Member
DW
Derek WatsonFractional CFO
Board
DB
David BarkerBoard director
VP
Vincent P. MihalikBoard director
RC
Ruel C. MercureBoard director
NU
Niles UtlautBoard director
DB
David BrunelBoard director
GA
Gregory AbbottBoard director
Reported raises · per SEC filings
Form D private placements$1.8M disclosed across 4 rounds · 2013–2017
▶$763.5KraisedNov 2017 · 9 investors · BiotechnologyRule 506(b)
▶$763.5KraisedNov 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ruel C. MercureDirector
- David BrunelDirector
- Niles UtlautDirector
- Gregory AbbottDirector
- David BarkerDirector
- Michael H.B. StowellExecutive Officer, Director
- Mikhail PlamExecutive Officer, Director
- Vincent P. MihalikDirector
- Offering amount
- $763.5K
- Amount sold
- $763.5K
- First sale
- Oct 2017
- Incorporated
- Limited Liability Company, Colorado
- Federal exemptions
- 06b
▶$396KraisedApr 2017 · 9 investors · BiotechnologyRule 506(b)
▶$396KraisedApr 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BarkerDirector
- Michael H.B. StowellExecutive Officer, Director
- Mikhail PlamExecutive Officer, Director
- Ruel C. MercureDirector
- Gregory AbbottDirector
- Vincent P. MihalikDirector
- David BrunelDirector
- Niles UtlautDirector
- Offering amount
- $768K
- Amount sold
- $396K
- First sale
- Apr 2016
- Incorporated
- Limited Liability Company, Colorado
- Federal exemptions
- 06b
▶$279.3KraisedJan 2015 · 5 investors · BiotechnologyRule 506(b)
▶$279.3KraisedJan 2015 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BarkerDirector
- Vincent P. MihalikDirector
- Michael H.B. StowellExecutive Officer, Director
- Ruel C. MercureDirector
- Mikhail PlamExecutive Officer, Director
- Niles UtlautDirector
- David BrunelDirector
- Gregory AbbottDirector
- Offering amount
- $1.1M
- Amount sold
- $279.3K
- First sale
- Dec 2014
- Incorporated
- Limited Liability Company, Colorado
- Federal exemptions
- 06b
▶$400KraisedMay 2014 · 4 investors · BiotechnologyRule 506(b)
▶$400KraisedMay 2014 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mikhail PlamExecutive Officer, Director
- Ruel C. MercureDirector
- Michael H.B. StowellExecutive Officer, Director
- Gregory AbbottDirector
- David BarkerDirector
- Vincent P. MihalikDirector
- Niles UtlautDirector
- Offering amount
- $750K
- Amount sold
- $400K
- First sale
- Dec 2013
- Incorporated
- Limited Liability Company, Colorado, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
IQVIA7 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Aadi Bioscience7 shared keywordsAadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition. It operates in the biotechnology and pharmaceutical sector.
Companies competing with AmideBio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $338.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does AmideBio do?
- AmideBio discovers and designs peptide therapeutics for metabolic diseases, using in-silico design and its BioPure process to produce ultrapure peptides. It also sells manufactured peptides and offers custom synthesis services to the biopharmaceutical industry and research community, aiming to license drug candidates at or before the IND stage.
- Who founded AmideBio?
- AmideBio was founded by Michael H. B. Stowell in 2009.
- How much funding has AmideBio raised?
- AmideBio has disclosed $1.8M raised across 4 rounds.
- Where is AmideBio headquartered?
- AmideBio is headquartered in Boulder, US.